Similar to the CD14+ immune effector cells, the tumor-infiltrated CD56+ cells from HER2+ breast cancer patients expressed high levels of HER2 and the CD56+ cells from luminal type breast cancer patient showed little HER2 expression (Additional file 1: Figure S2B). Here, ERBB2 is linked to breast carcinoma.